Kadmon Holdings LLC (NASDAQ:KDMN) shares traded down 4.1% during mid-day trading on Thursday . The stock traded as low as $9.27 and last traded at $9.35, with a volume of 148,610 shares. The stock had previously closed at $9.75.

Several research analysts have issued reports on the stock. HC Wainwright assumed coverage on shares of Kadmon Holdings in a report on Monday, August 22nd. They set a “buy” rating and a $25.00 target price on the stock. WBB Securities began coverage on shares of Kadmon Holdings in a report on Monday, August 1st. They issued a “sell” rating and a $7.50 price target on the stock. JMP Securities began coverage on shares of Kadmon Holdings in a report on Monday, August 22nd. They issued an “outperform” rating and a $16.00 price target on the stock. Citigroup Inc. began coverage on shares of Kadmon Holdings in a report on Monday, August 22nd. They issued a “neutral” rating and a $12.00 price target on the stock. Finally, Jefferies Group began coverage on shares of Kadmon Holdings in a report on Monday, August 22nd. They issued a “buy” rating and a $12.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Kadmon Holdings currently has an average rating of “Hold” and an average price target of $14.50.

The stock’s market cap is $77.64 million. The firm’s 50 day moving average price is $9.97 and its 200-day moving average price is $9.97.

In related news, major shareholder Daniel S. Loeb acquired 32,916 shares of Kadmon Holdings stock in a transaction that occurred on Friday, August 26th. The shares were purchased at an average cost of $9.98 per share, for a total transaction of $328,501.68. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Goldentree Asset Management Lp acquired 208,333 shares of Kadmon Holdings stock in a transaction that occurred on Monday, August 1st. The stock was bought at an average price of $12.00 per share, for a total transaction of $2,499,996.00. The disclosure for this purchase can be found here.

Kadmon Holdings, LLC is a biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of unmet medical need. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.